Clinical Trial Update: A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Ongoing Phase 2 clinical trial evaluating JYP0061 tablets for moderate-to-severe atopic dermatitis, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• JYP0061

Snippet

Sponsor: Guangzhou JOYO Pharma Co., Ltd | Conditions: Moderate-to-severe Atopic Dermatitis | Phase 2 | Status: ENROLLING_BY_INVITATION